Terns Pharmaceuticals (NASDAQ: TERN)
Terns Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Terns Pharmaceuticals Company Info
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
News & Analysis
Why Shares of Terns Pharmaceuticals Soared This Week
The company is showing progress toward a NASH therapy.
The Promises Behind Terns' Multi-Pronged Pipeline
This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.